{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Carcinoma&page=3", "query": { "condition": "Metastatic Thyroid Gland Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 134, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T19:51:48.017Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00668811", "title": "Sutent Adjunctive Treatment of Differentiated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Papillary Thyroid Cancer", "Follicular Thyroid Cancer", "Differentiated Thyroid Cancer" ], "interventions": [ { "name": "SU011248, Sutent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2020-08-05", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668811" }, { "nct_id": "NCT00104871", "title": "Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Insular Thyroid Cancer", "Recurrent Thyroid Cancer", "Stage II Follicular Thyroid Cancer", "Stage II Papillary Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-12", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 9, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104871" }, { "nct_id": "NCT04940052", "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Differentiated Thyroid Cancer (DTC)" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trametinib Placebo", "type": "DRUG" }, { "name": "Dabrafenib placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 153, "start_date": "2021-11-15", "completion_date": "2027-05-25", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 2, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940052" }, { "nct_id": "NCT04161391", "title": "Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET Gene Mutation", "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "TPX-0046", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-12-06", "completion_date": "2023-05-22", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 20, "location_summary": "La Jolla, California • Orange, California • Aurora, Colorado + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04161391" }, { "nct_id": "NCT05453799", "title": "Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Anaplastic Carcinoma", "Metastatic Thyroid Gland Oncocytic Carcinoma" ], "interventions": [ { "name": "Vudalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2022-07-21", "completion_date": "2030-09-05", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453799" }, { "nct_id": "NCT02012699", "title": "Integrated Cancer Repository for Cancer Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer", "Thyroid Cancer", "Lung Cancer", "Esophageal Cancer", "Thymus Cancer", "Colon Cancer", "Rectal Cancer", "Gastrointestinal Stromal Tumors", "Anal Cancer", "Bile Duct Cancer", "Duodenal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Liver Cancer", "Small Intestine Cancer", "Peritoneal Surface Malignancies", "Familial Adenomatous Polyposis", "Lynch Syndrome", "Bladder Cancer", "Kidney Cancer", "Penile Cancer", "Prostate Cancer", "Testicular Cancer", "Ureter Cancer", "Urethral Cancer", "Hypopharyngeal Cancer", "Laryngeal Cancer", "Lip Cancer", "Oral Cavity Cancer", "Nasopharyngeal Cancer", "Oropharyngeal Cancer", "Paranasal Sinus Cancer", "Nasal Cavity Cancer", "Salivary Gland Cancer", "Skin Cancer", "Central Nervous System Tumor", "Central Nervous System Cancer", "Mesothelioma", "Breast Cancer", "Leukemia", "Melanoma", "Sarcoma", "Unknown Primary Tumor", "Multiple Myeloma", "Ovarian Cancer", "Endometrial Cancer", "Vaginal Cancer", "Neuroendocrine Tumors", "Plasma Cell Dyscrasia", "Healthy Control" ], "interventions": [], "intervention_types": [], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "19 Years to 110 Years" }, "enrollment_count": 999999, "start_date": "2013-11-01", "completion_date": "2099-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 42, "location_summary": "Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more", "locations": [ { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Manchester", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012699" }, { "nct_id": "NCT00118248", "title": "Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2004-12", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118248" }, { "nct_id": "NCT01876784", "title": "Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Differentiated Thyroid Cancer" ], "interventions": [ { "name": "Vandetanib (SAR390530)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2013-09-17", "completion_date": "2022-01-22", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Torrance, California • Lexington, Kentucky + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Torrance", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01876784" }, { "nct_id": "NCT00124527", "title": "Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Irofulven + capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-03-31", "completion_date": "2006-08-31", "has_results": false, "last_update_posted_date": "2021-06-16", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 2, "location_summary": "Aurora, Colorado • Columbus, Ohio", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124527" }, { "nct_id": "NCT03099356", "title": "Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Thyroid Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2017-04-27", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-13T19:51:48.017Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03099356" } ] }